http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201992341-A8
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 |
| filingDate | 2018-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201992341-A8 |
| titleOfInvention | APPLICATION OF GLUTARIMIDE DERIVATIVES FOR TREATMENT OF DISEASES ASSOCIATED WITH ABERRANT CYTOKINE ACTIVITY |
| abstract | The invention relates to medicine and relates to the treatment of diseases associated with aberrant activity of fractalkine and monocytic chemoattractant proteins 1-4 (CCL2, CCL7, CCL8, CCL13), preferably, therapy of pain syndrome, fever, pneumonia, bronchitis, bronchiolitis, alveolitis, rheumatoid arthritis and psoriasis, as well as other diseases, through the use of a compound 1- (2- (1H-imidazol-4-yl) ethyl) piperidine-2,6-dione or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions containing a therapeutically effective amount of a compound of the invention. This compound, as well as its pharmaceutically acceptable salts, are highly effective in inhibiting the activity of the enzyme glutaminyl cyclase, which is involved, in particular, in the processes of post-translational modification of these cytokines. |
| priorityDate | 2017-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.